Liquid chromatography method for the quantitation of the breast cancer resistance protein ABCG2 inhibitor fumitremorgin C and its chemical analogues in mouse plasma and tissues

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 807, Issue 2, 2004, Pages 203-208

  Garimella, Tushar S ^a   Ross, Douglas D ^b,c,d   Bauer, Kenneth S ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

Breast cancer resistance protein; Fumitremorgin

Indexed keywords

CHEMICAL ANALYSIS; ENZYME INHIBITION; PROTEINS; TISSUE; TUMORS; ULTRAVIOLET DETECTORS;

ANTICANCER AGENTS; BREAST CANCER; CYTOTOXICITY;

LIQUID CHROMATOGRAPHY;

ACETONITRILE; AMMONIUM ACETATE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN INHIBITOR; FUMITREMORGIN C; KO 143; PROTEIN INHIBITOR; ROQUEFORTINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG POTENCY; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STANDARD; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDOLES; MICE; NEOPLASM PROTEINS; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 2942555477     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2004.04.008     Document Type: Article

References (12)

1. Rabindran S.K., He H., Singh M., Brown E., Collins K.I., Annable T., Greenberger L.M. Cancer Res. 58:1998;5850
2. Hazlehurst L.A., Foley N.E., Gleason-Guzman M.C., Hacker M.P., Cress A.E., Greenberger L.W., De Jong M.C., Dalton W.S. Cancer Res. 59:1999;1021
3. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M. Cancer Res. 60:2000;47
4. R.J. Cole, R.H. Cox, Handbook of Toxic Fungal Metabolites, Academic Press, New York, 1981, p. 355.
5. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., Schellens J.H., Koomen G.J., Schinkel A.H. Mol. Cancer Ther. 1:2002;417
6. Litman T., Druley T.E., Stein W.D., Bates S.E. Cell Mol. Life Sci. 58:2001;931
7. Nielsen P.V., Beuchat L.R., Frisvad J.C. Appl. Environ. Microbiol. 54:1988;1504
8. Cui C.B., Kakeya H., Okada G., Onose R., Osada H. J. Antibiot. (Tokyo). 49:1996;527
9. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., Floot B.G., Schellens J.H. Cancer Res. 59:1999;4559
10. FDA Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Center for Drug and Research (CDER), May 2001.
11. van Loevezijn A., Allen J.D., Schinkel A.H., Koomen G.J. Bioorg. Med. Chem. Lett. 11:2001;29
12. Frisvad J.C., Thrane U. J. Chromatogr. 404:1987;195